STRYCHNOS IGNATII SEED

N/A

Manufactured by Aurobindo Pharma Limited

27 FDA adverse event reports analyzed

Last updated: 2026-04-15

About STRYCHNOS IGNATII SEED

STRYCHNOS IGNATII SEED is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Aurobindo Pharma Limited. The most commonly reported adverse reactions for STRYCHNOS IGNATII SEED include ALOPECIA, FATIGUE, IMPAIRED HEALING, PAIN, WHITE BLOOD CELL COUNT DECREASED. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for STRYCHNOS IGNATII SEED.

Top Adverse Reactions

ALOPECIA3 reports
FATIGUE3 reports
IMPAIRED HEALING3 reports
PAIN3 reports
WHITE BLOOD CELL COUNT DECREASED3 reports
LUNG DISORDER2 reports
BREAST CANCER1 reports
GASTRITIS1 reports
HEADACHE1 reports
HYPONATRAEMIA1 reports
METASTASES TO LYMPH NODES1 reports
NAUSEA1 reports
SEIZURE1 reports
SYNCOPE1 reports
URINARY RETENTION1 reports
VOMITING1 reports

Report Outcomes

Out of 10 classified reports for STRYCHNOS IGNATII SEED:

Serious 80.0%Non-Serious 20.0%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female8 (100.0%)

Reports by Age

Age 882 reports
Age 411 reports
Age 531 reports
Age 711 reports
Age 273151 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with STRYCHNOS IGNATII SEED?

This profile reflects 27 FDA FAERS reports that mention STRYCHNOS IGNATII SEED. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for STRYCHNOS IGNATII SEED?

Frequently reported terms in FAERS include ALOPECIA, FATIGUE, IMPAIRED HEALING, PAIN, WHITE BLOOD CELL COUNT DECREASED, LUNG DISORDER. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures STRYCHNOS IGNATII SEED?

Labeling and FAERS entries often list Aurobindo Pharma Limited in connection with STRYCHNOS IGNATII SEED. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.